Atorvastatin Impurities: A Key Role in Hyperlipidemia Control and Prevention

Atorvastatin is a representative statin lipid-lowering drug and a cornerstone medication for the prevention and treatment of cardiovascular diseases .

According to Yaozhi.com data, from 2016 to the first half of 2025, atorvastatin calcium tablets ranked first in cumulative sales within the domestic public medical institution innovative drug market (based on brand sales), with total sales reaching 49.27 billion RMB, securing the top position in the Chinese new drug market over the past decade.

Statistics indicate that the number of people with dyslipidemia in China exceeds 400 million, with a prevalence rate of 35.6% among residents aged 18 and above. Currently, hyperlipidemia is showing a trend of affecting younger populations, with the dyslipidemia rate exceeding 40% in the 40-59 age group. Consequently, the demand for lipid control continues to grow.

Hyperlipidemia itself often presents with no obvious symptoms, but its primary hazard lies in gradually leading to atherosclerosis . This means cholesterol slowly deposits on the inner lining of blood vessels, much like scale in pipes, causing them to narrow and harden. When these plaques suddenly rupture, they can form thrombi that block crucial blood vessels, triggering life-threatening emergencies such as myocardial infarction (heart attack) and stroke .

Atorvastatin is a reductase inhibitor. Its core action is to inhibit the key enzyme for cholesterol synthesis (HMG-CoA reductase), thereby reducing cholesterol production in the liver . Simultaneously, it increases the synthesis of low-density lipoprotein (LDL) receptors, effectively clearing "bad cholesterol" (LDL cholesterol) from the blood and moderately increasing levels of "good cholesterol" (high-density lipoprotein cholesterol, HDL-C) . Furthermore, through multiple pathways such as anti-inflammatory, antioxidant effects, and improvement of vascular endothelial function, it plays a crucial role in stabilizing and reducing atherosclerotic plaques on arterial walls, which is vital for preventing acute events like heart attacks and strokes .

With the expansion of the atorvastatin market and the emergence of generic versions, drug quality and impurity control have become critical links in ensuring the efficacy and safety of this important lipid-lowering agent . Impurities that may arise during drug synthesis or storage can potentially affect efficacy or pose risks.

SZEB specializes in the supply of Atorvastatin impurity reference standards, offering a comprehensive portfolio of 100+ readily available products. This includes Atorvastatin EP impurities, Atorvastatin related compounds, Atorvastatin oxides, and various isomer impurities. For more information, please visit the official website: www.ex-biotech.cn . Consultation Hotline: 0755-23051186.